Skechers Opens First Flagship Store in Copenhagen
9.4.2026 09:00:00 CEST | Business Wire | Press Release
Expanding on its retail store network throughout Denmark, Skechers brings its revolutionary performance and lifestyle comfort technologies to Copenhagen with the city’s first Skechers flagship destination. Located in the heart of Amagertorv, the 700-square-meter store showcases the brand’s extensive offering of award-winning product worn by leading athletes around the globe, as well as its renowned innovations like Skechers Hands Free Slip-ins® and popular styles for all walks of life.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260409949016/en/
Skechers first flagship store in Copenhagen opens in the heart of Amagertorv.
“Skechers has experienced strong growth in the Nordics, particularly in Denmark. We have established a solid footprint across the region with 32 stores in the country, and our high-profile Copenhagen store has arrived at the right place and time to escalate our presence,” said Michael Greenberg, president of Skechers. “Offering physical galleries where customers can walk in, explore and experience our product firsthand has transformed every part of our brand—from our immersive World of Sports experiences to lifestyle and performance destinations. This all-encompassing flagship store joins our most prominent Skechers destinations around the globe—presenting Nordic consumers with the innovations, comfort, convenience and value that have made Skechers one of Europe’s fastest-growing names in footwear.”
“Our exceptional flagship retail space and Amagertorv’s high-traffic destination make it the perfect setting to connect our signature Comfort That Performs with locals and visitors from around the world,” added Peter Jørgensen, country manager of Skechers Nordics. “Amagertorv provides a premium space with maximum visibility alongside strong international and Danish brands where we can showcase the full breadth of our universe and offer a footwear experience beyond the ordinary.”
A re-imagination of mid-century design illuminated by state-of-the-art digital LED screens, Copenhagen-inspired graphics and even a giant Skechers Slip-ins® shoe, the modern space showcases the brand’s popular lifestyle footwear collections for every age and activity: from athleisure, fashion, casual and work styles for men and women to a dedicated section for children’s product. The store’s Skechers Performance area offers a gallery of the brand’s innovations, where athletes and enthusiasts can experience the brand’s extensive offering for running, football, golf, court/padel, basketball, and outdoor footwear.
Skechers collections are enhanced with the Company’s comfort innovations and game-changing performance technologies—including its Skechers Hyper Burst Pro™ Technology, Skechers Performance FitKnit® Technology, Skechers Hands Free Slip-ins® Technology, Skechers Glide-Step® Technology, Skechers Arch Fit® Technology, Skechers Max Cushioning® Technology and Skechers Air-Cooled Memory Foam® Technology. Shoppers will also enjoy a unique Skechers apparel and accessories range that will be new to Denmark.
The global roster of elite pros competing in Skechers footwear now includes Denmark football player Matt O’Riley along with Anthony Elanga, Harry Kane, Mohammed Kudus, Romeo Lavia and Barış Alper Yılmaz; basketball stars Joel Embiid, OG Anunoby, Julius Randle, Isaiah Hartenstein, Jackie Young, Rickea Jackson, and Kiki Iriafen; and golfers Brooke Henderson, Matt Fitzpatrick, Bernhard Langer and Max Greyserman.
The new location at Amagertorv 11, 1160 København K joins four Skechers concept stores in Copenhagen, as well as 27 locations across Denmark. Consumers can also shop at approximately 5,300 Skechers retail stores, online at skechers.dk, and at department stores and footwear retailers around the world.
About Sports Connection ApS and SKECHERS U.S.A., Inc.
Sports Connection ApS is a subsidiary of Skechers U.S.A., Inc., The Comfort Technology Company® based in Southern California. Skechers designs, develops and markets a diverse range of lifestyle and performance footwear, apparel and accessories for men, women and children. The Company’s collections are available in 180 countries and territories through department and specialty stores, and direct to consumers through skechers.com and approximately 5,300 Skechers retail stores. A Fortune 500® company, Skechers manages its international business through a network of wholly-owned subsidiaries, joint venture partners, and distributors. For more information, please visit about.skechers.com and follow us on Facebook, Instagram and TikTok.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260409949016/en/
Contacts
Media Contacts:
Peter Jørgensen
peter.jorgensen@skechers.com
Jennifer Clay
SKECHERS U.S.A., Inc.
jennc@skechers.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. The oral presentation of these data is taking place at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2026, in Chicago (Abstract #LBA7000. Session: Oral Abstract Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia. May 30, 4:00 – 7:00 p.m. ET [3:00 – 6:00 p.m.
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press Release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press Release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press Release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press Release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom